Are you interested in working in a specific topic? Now is your chance.
In the following you can find topics on which we are currently working. If you are interested in joining a Working Group, please write an email to membershipservice@esop.li
1. Development of quality standards (QuapoS)
Coordinator: Kristjan Kongi
Members: L. Bellante, P. Cavaco, C. Cortes, R. Gonec, H. Hirschinger, R. Khoueiry, A. Kokisheva, E. Korczowska, D. Lenssen, E. Moreno, G. Perego, T. Schöning, R. Terkola, C. van der Merwe, N. Waheed
2. Safe working and occupational exposure (MASHA)
Coordinator: Ewelina Korczowska
Aims of the MASHA working group:
The MASHA working group aims to provide the highest standards in the safe handling of anticancer drugs and to ensure safe working conditions for all professionals involved in cancer care. The MASHA working group will work towards these aims by providing standardized working procedures in a series of recommendations that can be implemented in a working environment of the members of ESOP. The objectives will be achieved by sharing knowledge and best practices and by performing independent research.
Requirements for participants in the MASHA working group:
-Be a member of ESOP
-Be a member of their national Society
-Secure funding from their own institution or country if they want to participate in MASHA research
-Be willing to share data, knowledge and experience within ESOP
Deliverables of the MASHA working group:
- Producing concise set of recommendations that each ESOP member can use in their own institution, covering the following subjects:
-Regular environmental monitoring program
-Safe and optimized cleaning protocols
-Guidelines for acquiring and using adequate PPEs
-Annual training on safe handling of cytotoxic drugs, including spillages
-Yellow hand activity - Advancing independent research that can further build upon current MASHA studies
-Surface contamination research outside Europe
-Contamination of cytotoxic drugs packaging
-Research on internal exposure of healthcare workers to anticancer drugs
(NB: both lists can be extended by the working group)
3. Compounding and GMP
Coordinator: Kristjan Kongi
4. Automation and robotization
Coordinator: Tilman Schöning
5. Oncology continuous education (EUSOP)
Coordinators: Christophe Bardin & Mina Kovacevic
6. Biosimilars
Coordinator: Marko Skelin
7. Supportive care for patients with cancer
Coordinator: Mirjam Crul
8. Pharmaco-economics
Coordinator: Robert Terkola
9. eHealth in oncology
Coordinators: Robert Terkola & Sherif Kamal
10. Clinical Pharmacy (1): patient counseling (on the ward/community pharmacy)
+ Clinical Pharmacy (2): checking prescriptions (medication reconciliation, drug drug interactions) (Pharmacovigilance)
Coordinators: Mirjam Crul & Christophe Bardin
Members: T. Assefa, A. Balogh, L. Bellante, L. Budau, P. Cavaco, C. Cortes, D. Eppel, S. Kamal, U. Khalid, M. Kuzmanovic, D. Reyes, C. Rioufol, O. Spasovska, M. E. Uda, A. Zegrean
11. Pharmacokinetics and Therapeutic Drug Monitoring
Coordinator: Christophe Bardin
12. Research
Coordinator: Robert Terkola
13. Oral cancer drugs
Coordinator: Jelena Rosentreter
Members: E. M. Afifi, A. Amidi, A. Balogh, A. Bello, Z. Bodor, L. Budau, C. Carbasse, D. Eppel, F. Festinese, A. Grzywa, S. Kamal, N. Kizilmese, M. Kuzmanovic, K. Meier, S Mira, I. Netikova, F. Ockert-Schön, C. Rioufol, M. Saar, C. Schramm, K. Vermis
14. Radiopharmacy
Coordinators: Michal Budinsky & Roman Gonec
15. Paediatric cancer
Coordinator: Svetlana Buraja
Members: T. Bauters, L. Bellante, T. Bilse, G. Casper, M. Ferreira, M. Galassi, A. Gizycka, Y. Hafidi, L. Hanff, L. Horvath, G. Indridadottir, S. Kamal, R. Khan, V. Ladisa, G. Lizega, K. Mache, B. Mohamed, C. Nehal, M. Ocokoljić, A. Parra Santolalla, M. Rayyan, M. Saar, F. Slimano, K. Wolber
